Prognosis and Genetic Characteristics of Patients with Plasma Cell Leukemia.
10.19746/j.cnki.issn.1009-2137.2020.06.003
- Author:
Yong-Li WU
1
;
Nan WANG
1
;
Ying-Zhao YAN
1
;
Li-Jun YUAN
1
;
Li-Li WANG
1
;
Hong-Hua LI
1
;
Meng LI
2
Author Information
1. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China,E-mail: limeng2016@yeah.net.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Hematopoietic Stem Cell Transplantation;
Humans;
In Situ Hybridization, Fluorescence;
Leukemia, Plasma Cell/genetics*;
Middle Aged;
Patients;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(6):1804-1810
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical characteristics, genetic abnormalities, treatment efficacy and prognostic factors in patients with plasma cell leukemia(PCL).
METHODS:30 patients diagnosed as PCL in our hospital from January 1993 to December 2019 were enrolled, and the clinical characteristics, laboratory findings, therapeutic regimes, and survival data of the patients were retrospectively analyzed.
RESULTS:The median age of the 30 patients was 56.5 (28-80) years old, among them, 25 patients were primary plasma cell leukemia, and 5 patients were secondary plasma cell leukemia. Complex karyotypes and subdiploids were most common in cytogenetic abnormalities. Among the 20 cases of chromosome G banding, 11 (55%) cases were complex karyotypes and 8 (40%) cases were hypodiploid. Fluorescent in situ hybridization (FISH) test showed that among 11 cases, 6 cases showed 17p13 deletion, 8 cases showed at least two kinds of abnormalities, which including t (14; 16), t (8; 14), t (11;14), 17p13 deletion, and 13q14 deletion. The median overall survival (OS) time was 10.5 months for all patients. The median OS time of the patients in ECOG score ≤ 2 group was 21.5 months, which was significantly longer than those in the ECOG score>2 group(1.2 months) (P=0.017). The median OS time of the patients treated with novel agents (including proteasome inhibitor and/or immunomodulator) was 24.9 months, which was significantly longer than the patients treated with traditional chemotherapy group(10.5 months) (P＜0.001). For the patients treated with novel agents, the median OS time of patients accepted two novel agents combination was 30.9 months, which was longer than those of single novel agent(11.5 months) (P=0.021). The effect of genetic abnormolity to the OS of the patients showed no statistical difference. Multivariate statistical analysis showed that ECOG score>2 was the independent prognostic factor of plasma cell leukemia patients. There were two patients underwent allogeneic hematopoietic stem cell transplantation in the study,but died due to the pulmonary infection within 6 months after transplantation.
CONCLUSION:In the era of novel agents, ECOG score is an independent prognostic factor of plasma cell leukemia. Multiple novel agents treatment should be underwent as soon as possible to improve the prognosis of the patients. Pulmonary infection is a common factor that cause the death of the patients after allogeneic hematopoietic stem cell transplantation.
